TY - JOUR T1 - Nedaplatin and Irinotecan in Patients with Large-cell Neuroendocrine Carcinoma of the Lung JF - Anticancer Research JO - Anticancer Res SP - 1453 LP - 1456 VL - 32 IS - 4 AU - YOSHIYUKI KENMOTSU AU - FUMIHIRO OSHITA AU - MAKIKO SUGIURA AU - SHUJI MURAKAMI AU - TETSURO KONDO AU - HARUHIRO SAITO AU - KOUZO YAMADA Y1 - 2012/04/01 UR - http://ar.iiarjournals.org/content/32/4/1453.abstract N2 - Background: No standard chemotherapy has been established for patients with large-cell neuroendocrine carcinoma (LCNEC). Patients and Methods: Patients with LCNEC of the lung were treated with nedaplatin (NP) at 50 mg/m2 and irinotecan at 50 mg/m2 on days 1 and 8 every four weeks for four cycles. Results: Data for 18 of the LCNEC patients were retrospectively analyzed. All patients were male, with a performance status 0 or 1, and the median age was 68 (range 58-80) years. Nine patients received adjuvant chemotherapy after undergoing complete surgical resection. Fourteen patients were able to receive four cycles of nedaplatin and irinotecan. Grade 4 leukopenia and neutropenia occurred in 5.6% and 16.7%, respectively. Four patients experienced grade 3 non-hematologic toxicities, such as diarrhea, enterocolitis, duodenal perforation and myocardial infarction. There were no treatment-related deaths. Two patients achieved complete response and four achieved partial response, and the median survival time was 12.3 months for the nine patients with advanced disease. Conclusion: Nedaplatin plus irinotecan is effective and safe for patients with LCNEC of the lung. ER -